Merck has decided to discontinue the development of its osteoporosis drug and will not seek regulatory approval for its use. The decision follows an independent review of the treatment that confirmed an increased risk of stroke. Merck Research Laboratories President Roger Perlmutter says the drugmaker was disappointed that overall benefit-risk profile for the drug does not support filing or further development.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
